Objective Endometriosis is a chronic and disabling gynecological disease affecting 10% of women of reproductive age, representing 176 million patients worldwide. It is defined as the presence of endometrial-like tissue outside the uterus, capable of invading several organs. It is associated with acute symptoms, mainly consisting of severe pelvic pain and infertility, imposing an annual economic burden estimated at $77,46 billion in 9 European countries and $78.05 billion in the USA.The current gold standard for diagnosis of endometriosis is an invasive surgical procedure performed under general anesthesia (laparoscopy) enabling the visualization of the lesions by the surgeon and histological confirmation. Once diagnosed, endometriosis management frequently combines surgery and non-specific hormonal therapies with limited efficacy. Since these treatments only address the symptoms and not the root causes, disease recurrence is frequent and occurs in up to 50% of the patients.In close collaboration with international endometriosis experts, Endodiag has developed EndoSearch®, a unique noninvasive diagnostic solution based on endometrium tissue analysis, which assesses the presence or absence of endometriosis without surgery, helping the physician to make his diagnosis rapidly, cost-effectively, with a non invasive procedure and enabling him to take decisions on the most suitable patient management.With this research programme, Endodiag is addressing a major healthcare need, clearly identified by the European Community in its statement of June 2005 at the European parliament. EndoSearch® successful validation and deployment will improve the quality of life of millions of patients while significantly reducing endometriosis-associated healthcare costs. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinegynaecologyreproductive medicinemedical and health sciencesclinical medicinesurgerysurgical proceduressocial scienceseconomics and businesseconomicshealth economics Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator ENDODIAG Net EU contribution € 4 231 613,00 Address 4 rue pierre fontaine pepiniere genopole enterpris 91058 Evry France See on map Region Ile-de-France Ile-de-France Essonne Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 215 378,25
